ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
07/28/201617:12:36Current Report Filing (8-k)
07/28/201617:00:00Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh...
07/28/201617:00:00Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh...
07/28/201601:00:00Pharming Reports on Financial Results for the First Six Months...
07/26/201608:30:00Progenics Receives $50 Million Milestone Payment Following FDA...
07/22/201617:00:00Toronto Stocks Rise as Earnings Offset Falling Oil and Gold Prices
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/19/201621:40:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201621:02:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201619:19:00Valeant, Progenics Shares Rise on Constipation Drug Approval
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201617:48:00Valeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/18/201601:00:00Pharming Announces Positive Results from Randomized Controlled...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/14/201609:43:00Valeant's Ex-CEO Michael Pearson Sells Nearly $100 Million in...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad